4th Quarter - Report — NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION (2018)

Firm

NATIONAL KIDNEY FOUNDATION

Client

NATIONAL KIDNEY FOUNDATION

Income

—

Expenses

$100,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2019 Appropriations for the Department of Health and Human Services (NIH, CDC, HRSA); Food and Drug Administration; Department of Veterans Affairs, Indian Health Service, Department of Defense (medical research)

Lobbyist	Covered position, as disclosed
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC)

Health Issues HCR

Initiatives to increase and facilitate organ donation and transplantation, including H.R.1270 (Living Donor Protection Act) and build support for a Senate companion bill. Comments on proposed policies by the Organ Procurement and Transplantation Network and United Network for Organ Sharing. Prescription Drug Pricing H.R. 2644 and S. 1890, Chronic Kidney Disease Improvement in Research and Treatment Act of 2017. Health and Human Services Million Hearts initiative. Health and Human Services KidneyX initiative. Management of the Patient Protection and Affordable Care Act. Repeal and Replacement of Affordable Care Act.

Lobbyist	Covered position, as disclosed
ANDREW W. FULLERTON	—
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); SENATE

Bills named: H.R. 1270 (115th), H.R. 2644 (115th), S. 1890 (115th)

Medicare/Medicaid MMM

Initiatives to support early detection and management of Chronic Kidney Disease (H.R. 3867). Proposed Alternative Payment Model for Chronic Kidney Disease care. Comments on Efficiency and Transparency Transplant Conditions of Participation, including organ discards. Comments on Proposed Rule Making for Part B drugs. Medicare Part D Protected Classes status. Increased utilization of home kidney dialysis. Medicare coverage of immunosuppressive drugs for kidney transplant recipients.

Lobbyist	Covered position, as disclosed
ANDREW W. FULLERTON	—
TONYA SAFFER	—
TROY ZIMMERMAN	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); SENATE; Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ)

Bills named: H.R. 3867 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.